Abstract
In this multcenter, international, randomized controlled trial, Tung et al (Circulation May 4, 2022; doi:10.1161/CIRCULATIONAHA.122.060039, PMID 35507499) sought to assess the efficacy of early catheter ablation of ventricular tachycardia (VT) at the time of implantable cardioverter-defibrillator (ICD) implantation as compared with conventional therapy. The Pan-Asia United States Prevention of Sudden Cardiac Death trial enrolled patients from centers in China, Japan, South Korea, and Taiwan who had structural heart disease (SHD) and an indication for secondary prevention ICD or who had VT inducible at the time of electrophysiology study (EPS) and met criteria for primary prevention ICD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
